Hims & Hers to start selling peptides this month
Also in this issue: California halts a Tampa pharmacy's shipments
Forwarded this? Get it weekday mornings.
Take. Hims & Hers plans to sell peptides this month to a base of nearly 2.8 million subscribers. Expect peptide ads to cost clinics more. Patients who came to a clinic because nobody else sold peptides will start comparing prices.
Hims & Hers will start selling sermorelin, glutathione and NAD+ in November, Reuters reports from the company's Monday earnings. BPC-157 and TB-500 come later. CEO Andrew Dudum said Hims will manufacture those two in the U.S. CFO Yemi Okupe said peptide revenue should be immaterial through the year. In a letter posted the same day, Dudum wrote: "Next is Peptides+, with clinician-led treatment plans and access to regular blood testing to monitor progress."
Enhanced Group got there first. The company runs the Live Enhanced telehealth platform. Its Nov. 3 release says it began prescribing BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax that day, filled by licensed U.S. pharmacies. Enhanced also says FDA's advisory committee is expected to review more peptides in February 2027. That date is Enhanced's expectation.
Hims and Enhanced both build on a draft HHS policy in the Federal Register. HHS would hold off enforcement against 503A pharmacies that compound six listed peptides under its conditions. It approves no drug. Comments close Friday, Nov. 13. The American Medical Association wants the policy gone. On Monday its delegates told the AMA to urge HHS and FDA to "immediately rescind" policies that ease compounding of unapproved synthetic peptides. They also want it to work with state medical and pharmacy boards to "pursue swift enforcement actions against compounding pharmacies, direct-to-consumer telehealth platforms, and online dispensaries" selling them. The AMA can lobby HHS. It can't change the policy.
| When | Who | Side | Status |
|---|---|---|---|
| Tue, Nov. 3 | Enhanced | Selling six peptides by prescription | Past, live |
| Monday | AMA | Urges HHS and FDA to rescind the policy | Past |
| Fri, Nov. 13 | HHS | Comments close on the 503A peptide policy | Tomorrow |
| November | Hims & Hers | First peptide phase launch | Company target |
Enhanced already sells BPC-157 and TB-500. Hims says those two come later.
New here? Sign up free to get ODR every weekday morning.
Enforcement Watch
California orders Tampa pharmacy to stop shipping into the state
The California State Board of Pharmacy ordered Logos Pharmacy, a Tampa compounder, to stop sending compounded drugs to California patients. The cease-and-desist order is dated Oct. 15. The board says Logos shipped at least 23,877 prescriptions into California from August 2025 to mid-September 2026 without a nonresident pharmacy license. About 13,765 were sterile compounded preparations, which need a separate California license. Every one of those prescriptions came from three telehealth platforms: EONMeds, Overtime Men's Health and WellMedr. The order is against Logos alone. Logos can request a hearing to contest it.
California's board traced Logos's volume back to the telehealth brands that sent it. In our read, a pharmacy's missing California license is now the platform's problem too.
The Signal
Telehealth
Five states join FTC privacy suit against Hims & Hers
Arizona, Florida, Nebraska, Ohio and Wisconsin joined the FTC's lawsuit against Hims & Hers, Reuters reports, citing an FTC statement. Utah and Los Angeles County joined when the FTC sued in July. The amended complaint in federal court in Northern California alleges Hims shared health information with ad platforms including Meta and Snap despite its privacy claims. It also alleges Hims charged users for prescriptions before they met a provider and made subscriptions hard to cancel. The states add their own consumer protection laws to the federal claims. These are allegations. A Hims spokesperson told Reuters the company will "vigorously defend ourselves against these follow-on claims." The FTC's theory covers any membership clinic that bills at intake or runs ad pixels on intake pages.
Telehealth
REMEVi cuts compounded GLP-1 prices for prepaid plans
REMEVi, a bilingual telehealth platform, lists compounded semaglutide at $96 a month and tirzepatide at $168 on its pricing page. Those rates require prepaying 12 months, or $1,248 and $2,184. Month-to-month, the same drugs cost $143 and $224. The page says each "month" is four weeks. A prepaid year buys 13 fills.
Everyone
OptiMantra prices its AI scribe at $19 a provider
OptiMantra launched a built-in AI scribe at $19 per provider per month, per its release. It records the visit with consent and drafts the chart note.
Wire
- LifeMD reports third-quarter results today at about 4:05 p.m. ET, per its rescheduling release.
- DEA's special-registration rule for telemedicine prescribing is still under White House review on reginfo.gov. The 90-day mark is Monday, Nov. 23, with one 30-day extension allowed.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.